PMV Pharmaceuticals, Inc. Overview
Pro stress-test →PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53 mutations in cancer, with PC14586 as its lead product candidate that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company recently published first-in-human rezatapopt data in the New England Journal of Medicine in February 2026, demonstrating selective reactivation of mutant p53 in advanced solid tumors.
Strategic Profile
Pro stress-test →PMV has aligned with the FDA on critical aspects of the Phase 2 registrational PYNNACLE trial, with encouraging response rates observed across multiple cancer types including ovarian, breast, small-cell lung, and endometrial cancers. The company's benign safety profile enables effective combinations with other agents like Keytruda, potentially broadening treatment options.
Competitive Landscape
Pro stress-test →PMV operates in precision oncology focusing on p53 mutation targeting with tumor-agnostic small molecule therapies, competing in a space where other biotech firms pursue p53-targeted approaches. The company's Y220C mutation focus provides a defined patient population advantage versus broader p53 programs.
Industry Context
PMV Pharmaceuticals, Inc. operates in Precision Oncology / Biotech.
Key facts
Founded: 2013 · Headquarters: Princeton, New Jersey · Revenue: $0 · Market cap: $55-90M